Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy
Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy is a paper indexed in PICO Portal from OpenAlex.
How many citations does Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy have?
Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy has 236 citations in the OpenAlex counts PICO Portal stores.
When was Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy published?
Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy has 2008 year in the PICO Portal index.
What is the open-access status of Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy?
Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy has green oa status in the PICO Portal index.
What is the DOI of Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy?
The DOI for Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy is on the source record.
What is the PMID of Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy?
The PMID for Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy is on the source record.
What is the OpenAlex record for Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy?
The OpenAlex for Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy is on the source record.